Tradestie Institutional Equity Comparison Engine

XPH vs PJP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PJP Overall Edge

PJP Captures Institutional Edge (2โ€“0 Pillars ยท 3โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Invesco Pharmaceuticals ETF (PJP) driven by superior Momentum & Technical, Options & Structure. Fundamentally, XPH trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus PJP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, XPH sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against PJP sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
XPH N/M vs PJP N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner PJP
1Y +30.6% vs +28.1% ยท 52W Pos 64% vs 93%
Options & Structure Winner PJP
UNCLASSIFIED (5th %ile IV) vs UNCLASSIFIED (2nd %ile IV)
XPH NYSE Arca
SPDR S&P Pharmaceuticals ETF
Institutional Equity
$65.58
-1.87% 1D
Market Cap N/A
1M Return +6.05%
1Y Return +30.61%
Forward P/E N/M
Unified AI Score
41.0 / 100 SELL
Tech 37.0 Fund 45.0 Flow 50.0 Mom 50.0
PJP NYSE Arca
Invesco Pharmaceuticals ETF
Institutional Equity
$130.10
-0.72% 1D
Market Cap N/A
1M Return +4.53%
1Y Return +28.09%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XPH +30.61% PJP +28.09% Spread: +2.52 pp (XPH Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XPH TTM Op. Margin: N/A PJP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XPH vs PJP. Trailing 12-month operating profitability (XPH N/A vs PJP N/A) and valuation multiples (XPH N/M vs PJP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XPH (0) vs PJP (3)
Institutional Metric XPH PJP Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 64% ($50โ€“$74) 93% ($99โ€“$133) Stronger Trend PJP
Beta / 30D Volatility Risk Regime 0.87ฮฒ ยท 32% Vol 0.45ฮฒ ยท 23% Vol Lower Realized Risk PJP
Unified Institutional Score Composite Signal 41.0 / 100 (SELL) 50.1 / 100 (HOLD) Higher Composite PJP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XPH vs PJP Buy Guide
XPH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live XPH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PJP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live PJP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XPH nor PJP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.